ondansetron has been researched along with Anticipatory Vomiting in 19 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 9.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| "We investigated the efficacy of combination of ondansetron hydrochloride injection and tablet against nausea and vomiting in 22 lung cancer patients (total number of chemotherapy courses: 23) receiving chemotherapy of single-dose carboplatin (CBDCA) at a dose of 302." | 9.09 | [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin]. ( Miyamoto, Y; Oomasa, M; Teramachi, M; Tomiyama, K; Yagi, K, 1999) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 9.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 7.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 7.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "Investigated the prevalence of anticipatory nausea and vomiting (ANV) among 59 pediatric cancer patients who had routinely received ondansetron (Zofran) antiemetic therapy and determined patient- and treatment-related factors associated with ANV." | 7.69 | Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. ( Barclay, DR; Bieberich, AA; Mulhern, RK; Smith, BF; Tyc, VL, 1997) |
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 5.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| "We investigated the efficacy of combination of ondansetron hydrochloride injection and tablet against nausea and vomiting in 22 lung cancer patients (total number of chemotherapy courses: 23) receiving chemotherapy of single-dose carboplatin (CBDCA) at a dose of 302." | 5.09 | [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin]. ( Miyamoto, Y; Oomasa, M; Teramachi, M; Tomiyama, K; Yagi, K, 1999) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 5.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 3.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 3.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "Investigated the prevalence of anticipatory nausea and vomiting (ANV) among 59 pediatric cancer patients who had routinely received ondansetron (Zofran) antiemetic therapy and determined patient- and treatment-related factors associated with ANV." | 3.69 | Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. ( Barclay, DR; Bieberich, AA; Mulhern, RK; Smith, BF; Tyc, VL, 1997) |
| " Two cases of adverse reactions (hiccups and elevation of ALT and BUN) were observed in the DEX group; however, since the symptoms were all mild, we did not consider there was any problem in safety." | 2.70 | [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin]. ( Furue, H; Horichi, N; Ikeda, M; Taguchi, T; Tsukakoshi, S, 2001) |
| " Adverse reactions were observed in 2 cases (2 reports of headache) in the OND group and 5 cases (2 reports of hiccups, 2 headache, 2 diarrhea, one constipation, one hot facial flushes and one elevation of gamma-GTP) in the DEX group; however, since the symptoms were all mild, we did not consider there was any problem in safety." | 2.70 | [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin]. ( Eguchi, F; Furue, H; Ikeda, M; Taguchi, T; Tsukakoshi, S, 2001) |
| "A group of 90 breast cancer patients undergoing chemotherapy were assessed prospectively to estimate the prevalence of acute (post-treatment) and anticipatory emesis in the 1990s." | 1.29 | Acute and anticipatory emesis in breast cancer patients. ( Casado, A; Diaz-Rubio, E; Fernández-Marcos, A; López Martin, JA; Martín, M; Rodriguez-Lescure, A; Sanchez, JJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (47.37) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, ZK | 1 |
| Feng, RX | 1 |
| Wang, YL | 1 |
| Parker, LA | 1 |
| Kwiatkowska, M | 1 |
| Mechoulam, R | 1 |
| Marty, M | 1 |
| Richard, A | 1 |
| d'Allens, H | 1 |
| Fernández-Marcos, A | 1 |
| Martín, M | 1 |
| Sanchez, JJ | 1 |
| Rodriguez-Lescure, A | 1 |
| Casado, A | 1 |
| López Martin, JA | 1 |
| Diaz-Rubio, E | 1 |
| Tyc, VL | 1 |
| Mulhern, RK | 1 |
| Barclay, DR | 1 |
| Smith, BF | 1 |
| Bieberich, AA | 1 |
| Sawaguchi, K | 1 |
| Yabushita, H | 1 |
| Tsukada, H | 1 |
| Yamada, H | 1 |
| Noguchi, M | 1 |
| Nakanishi, M | 1 |
| Miyamoto, Y | 1 |
| Yagi, K | 1 |
| Teramachi, M | 1 |
| Oomasa, M | 1 |
| Tomiyama, K | 1 |
| Miyashita, M | 1 |
| Onda, M | 1 |
| Ikeda, K | 1 |
| Bando, K | 1 |
| Hagiwara, N | 1 |
| Tsuchiya, Y | 1 |
| Yoshiyuki, T | 1 |
| Kiyama, T | 1 |
| Saito, T | 1 |
| Sasajima, K | 1 |
| Yamashita, K | 1 |
| Sasaki, K | 1 |
| Yanagida, T | 1 |
| Ohya, M | 1 |
| Ishikawa, H | 1 |
| Oge, A | 1 |
| Alkiş, N | 1 |
| Oge, O | 1 |
| Kartum, A | 1 |
| Zhou, J | 2 |
| Xu, B | 2 |
| Zhou, A | 2 |
| Huang, J | 1 |
| Wang, Z | 1 |
| Zhou, L | 1 |
| Horichi, N | 1 |
| Taguchi, T | 2 |
| Furue, H | 2 |
| Ikeda, M | 2 |
| Tsukakoshi, S | 2 |
| Eguchi, F | 1 |
| Nishida, T | 1 |
| Yakushiji, M | 1 |
| Ohizumi, K | 1 |
| Noda, S | 1 |
| Rikimaru, T | 1 |
| Matsuoka, K | 1 |
| Kodama, F | 1 |
| Mohri, H | 1 |
| Motomura, S | 1 |
| Fukawa, H | 1 |
| Tanabe, J | 1 |
| Koharasawa, H | 1 |
| Kanamori, H | 1 |
| Hashimoto, Y | 1 |
| Harano, H | 1 |
| Sakai, R | 1 |
| Tomita, N | 1 |
| Fujimaki, K | 1 |
| Takemura, S | 1 |
| Hattori, M | 1 |
| Ishida, T | 1 |
| Kusaba, T | 1 |
| Hayakawa, H | 1 |
| Blower, P | 1 |
| Aapro, M | 1 |
10 trials available for ondansetron and Anticipatory Vomiting
| Article | Year |
|---|---|
[Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cross-Over Studies | 1999 |
[Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Female; Humans; Inj | 1999 |
Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Cost-Benefit Analysis; Female; Granisetron; Hu | 2000 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Child; Child, Prescho | 1997 |
[A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Female; Humans; | 1998 |
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Femal | 2001 |
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Gen | 2001 |
[Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Sched | 2002 |
[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2002 |
9 other studies available for ondansetron and Anticipatory Vomiting
| Article | Year |
|---|---|
[Current status and direction of researches on antagonizing chemical agents induced vomiting by Chinese and Western medicines].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Neoplasms; Ondanset | 2004 |
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting.
Topics: Analysis of Variance; Animals; Antiemetics; Association Learning; Cannabidiol; Cannabinoids; Conditi | 2006 |
[Antiemetic effect of ondansetron in recurrent chemotherapy with cisplatin].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Male; Middle Aged; Ondansetr | 1993 |
Acute and anticipatory emesis in breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; | 1996 |
Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy.
Topics: Adolescent; Antiemetics; Case-Control Studies; Child; Conditioning, Classical; Female; Humans; Male; | 1997 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |
Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Topics: Afferent Pathways; Antiemetics; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cross-Ov | 2002 |